Diego A. Díaz García, Medical Oncologist /CEO/Founder at CánCare – High Specialty in Oncology, shared a post on X:
“Preventing moderate to severe dermatologic AE in 1L EGFR-mutant advanced NSCLC treatment with amivantamab plus lazertinib COCOON Phase 2 trial.
COCOON DM reduced grade two or greater dermatologic AEs by 50% vs SoC DM.”
